From ACC 2024 - STEP HFpEF DM: Semaglutide 2.4 mg Improves Functional Status, Symptoms in Patients with Diabetes, HFpEF
New data presented at the American College of Cardiology 2024 (ACC.24) Annual Scientific Sessions underlines the benefits of semaglutide in patients with heart failure with preserved ejection fraction (HFpEF), specifically those with concomitant diabetes mellitus and obesity.1
Presented by Mikhail Kosiborod, MD, results of the STEP HFpEF DM trial reaffirm the beneficial effects of semaglutide 2.4 mg (Wegovy) on quality of life and physical symptoms associated with HFpEF seen in the original STEP HFpEF trial.
Source: MDMag
To view the third party content, kindly click on the link below or read more. You will then leave this site and enter a third party site.
